Weight-Loss Drugmaker Lilly Surpasses Tesla in Value After $85 Billion Wipeout
- Obesity-drug frenzy made Lilly most valuable health-care firm
- Tesla battered after disappointing earnings, growth concerns
This article is for subscribers only.
Weight-loss drug innovators have unseated electric-car makers as some of 2024’s must-own stocks.
Tesla Inc.’s $80 billion wipeout, spurred by investor anxiety about slowing growth, led to Eli Lilly & Co. overtaking the carmaker in market value Thursday.